Compared to low-risk HCC patients, high-risk HCC patients had greater levels of the immune checkpoint molecules, CTLA-4 and LMTK3, indicating that they may be more responsive to therapy using immune checkpoint inhibitors CTLA-4 and LMTK3 (Figure 8D). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.